Assenagon Asset Management S.A. Boosts Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Assenagon Asset Management S.A. boosted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 3.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 562,929 shares of the company’s stock after purchasing an additional 16,392 shares during the quarter. Assenagon Asset Management S.A. owned about 0.18% of Amneal Pharmaceuticals worth $3,575,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Arizona State Retirement System purchased a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth about $183,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Amneal Pharmaceuticals in the fourth quarter valued at $187,000. New York State Common Retirement Fund increased its position in Amneal Pharmaceuticals by 149.1% in the fourth quarter. New York State Common Retirement Fund now owns 122,003 shares of the company’s stock worth $741,000 after purchasing an additional 73,020 shares during the last quarter. Truist Financial Corp bought a new stake in Amneal Pharmaceuticals in the fourth quarter worth $395,000. Finally, Swiss National Bank purchased a new stake in Amneal Pharmaceuticals during the fourth quarter valued at $1,291,000. Institutional investors own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

AMRX has been the subject of a number of recent research reports. Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. The Goldman Sachs Group boosted their price objective on Amneal Pharmaceuticals from $6.25 to $8.00 and gave the stock a “buy” rating in a research note on Monday, May 6th. Finally, Truist Financial raised their price objective on Amneal Pharmaceuticals from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Amneal Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $9.00.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX opened at $8.15 on Tuesday. The company has a current ratio of 1.65, a quick ratio of 0.97 and a debt-to-equity ratio of 121.31. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of -14.55 and a beta of 1.23. Amneal Pharmaceuticals, Inc. has a 12 month low of $3.36 and a 12 month high of $8.28. The firm’s 50-day moving average is $7.11 and its 200 day moving average is $6.40.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.